| Risk of metabolic abnormalities in patients infected with HIV receiving antiretroviral therapy that contains lopinavir-ritonavir. | |
| | |
MedLine Citation:
|
PMID: 15034836 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The evolution of fasting glucose, triglyceride, and total and high-density lipoprotein (HDL) cholesterol level and the factors associated with development of clinically significant abnormalities in these metabolic parameters at 6 months were assessed in 353 consecutive human immunodeficiency virus (HIV)-infected patients who were receiving antiretroviral therapy containing lopinavir-ritonavir. Although glucose and HDL cholesterol levels did not change, triglyceride and total cholesterol levels significantly increased (P<.0001 for each), as did the proportion of patients with a triglyceride level of >400 mg/dL and a total cholesterol level of >240 mg/dL (P=.002). A baseline triglyceride level of >400 mg/dL and a baseline total cholesterol level of >240 mg/dL were identified as independent factors predicting clinically significant hypertriglyceridemia and hypercholesterolemia, respectively, at 6 months. These findings may have clinical implications when the therapeutic option of lopinavir-ritonavir is considered. |
| | |
Authors:
|
Esteban Martínez; Pere Domingo; María J Galindo; Ana Milinkovic; Juan A Arroyo; Francisco Baldovi; María Larrousse; Agathe León; Elisa de Lazzari; José M Gatell |
Related Documents
:
|
1524076 - Increased triglyceride levels in shift workers. 8892766 - Changes in plasma lipids and lipoproteins associated with starting or stopping postmeno... 12698776 - Transdermal contraceptive patch delivering norelgestromin and ethinyl estradiol. effect... 21443486 - Olive oil and haemostasis: platelet function, thrombogenesis and fibrinolysis. 1621256 - Effects of a phytoestrogen diet on estrogen-dependent reproductive processes in immatur... 8492716 - Effects of cholesterol uptake from high-density lipoprotein on bile secretion and 3-hyd... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2004-03-15 |
Journal Detail:
|
Title: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America Volume: 38 ISSN: 1537-6591 ISO Abbreviation: Clin. Infect. Dis. Publication Date: 2004 Apr |
Date Detail:
|
Created Date: 2004-03-22 Completed Date: 2004-04-08 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 9203213 Medline TA: Clin Infect Dis Country: United States |
Other Details:
|
Languages: eng Pagination: 1017-23 Citation Subset: IM |
Affiliation:
|
Hospital Clínic-Institut d'Investigaciones Biomèdiques August Pi i Sunyer, Valencia, Spain. esteban@fundsoriano.es |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Antiretroviral Therapy, Highly Active Cholesterol / metabolism Cholesterol, HDL / metabolism Female HIV HIV Infections / complications*, drug therapy HIV Protease Inhibitors / adverse effects* Humans Male Metabolic Diseases / chemically induced*, epidemiology Pyrimidinones / adverse effects* Risk Factors Ritonavir / adverse effects* Triglycerides / metabolism |
| Chemical | |
Reg. No./Substance:
|
0/Cholesterol, HDL; 0/HIV Protease Inhibitors; 0/Pyrimidinones; 0/Ritonavir; 0/Triglycerides; 192725-17-0/lopinavir; 57-88-5/Cholesterol |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Clinical features related to antiphospholipid syndrome in patients with chronic viral infections (he...
Next Document: Changes in hepatitis B virus DNA levels with acute HIV infection.